On April 10, 2026, 4Life announced a landmark achievement in nutritional science with the launch of 4Life Transfer Factor® MAX, the first product in the world to feature plant-derived transfer factors. Long believed by the scientific community to exist only in mammals and avians, transfer factors—immune system peptides responsible for recognizing, responding to, and remembering immune challenges—have now been identified in plants—marking a significant paradigm shift in immunological research.
This breakthrough is the result of a seven-year collaboration between 4Life and UNIGEN, a Washington-based plant research laboratory. Through the screening of thousands of plant species, researchers discovered transfer factors in the seed of Brassica napus. 4Life has named these plant-based transfer factors PhytoFactor™, a patent-pending innovation that is expected to yield an additional United States Patent and Trademark Office (USPTO) patent. This discovery is not immune-signaling peptides but only expands the scientific understanding of immune-signaling peptides and also opens up new possibilities for plant-based supplementation.
To validate their findings, UNIGEN and 4Life’s Research and Development team published two peer-reviewed studies in international journals. One article, featured in Molecules, examined the discovery second, published and in vitro immunological activity of plant-derived transfer factors. The second, published in the International Journal of Applied Sciences, provided a proteomics comparison between animal- and plant-based transfer factors. Together, these publications offer a robust scientific foundation for the company’s claims and underscore the rigor of its research process.
4Life Transfer Factor® MAX is formulated with a comprehensive blend of ingredients designed to support immune function. It includes 300 milligrams of PhytoFactor, 600 milligrams of the company’s proprietary Tri-Factor® Formula, a clinical dose of IP-6 (inositol hexaphosphate), a mushroom blend, and essential micronutrients such as vitamin C, vitamin D, and zinc. According to Chief Scientific Officer Dr. David Vollmer, the formulation represents an historic advancement in immune system supplementation.
The product is further supported by three gold-standard clinical studies. These demonstrated the natural production of millions of immune stem cells, measured the activity of neutrophils, and identified immune system activation within as little as two hours. While these findings have not been evaluated by the FDA or international health authorities, they contribute to a growing body of evidence supporting the product’s structure and function claims.
4Life’s commitment to scientific excellence is reflected in its extensive portfolio, which includes more than 80 patents, over 50 peer-reviewed publications, and numerous third-party studies. The company has also received multiple industry recognitions, including the World Plant-Based Protein Innovation Award in 2024, the Globee Award for Most Innovative Company in 2025, and the Global 100 designation as the Best Plant-Based Immune System Nutraceutical Manufacturer of 2026.
4Life Founder David Lisonbee has consistently prioritized research and innovation. The launch of Transfer Factor® MAX reinforces the company’s founding vision and positions it at the forefront of a new era in plant-based immune support.
For more information, visit 4Life – The Immune System Company®
